By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Wealth Beat NewsWealth Beat News
  • Home
  • News
  • Finance
  • Investing
  • Banks
  • Mortgage
  • Loans
  • Credit Cards
  • Small Business
  • Dept Management
Notification Show More
Aa
Wealth Beat NewsWealth Beat News
Aa
  • News
  • Finance
  • Investing
  • Banks
  • Mortgage
  • Loans
  • Credit Cards
  • Small Business
  • Dept Management
Follow US
Wealth Beat News > News > Meta Platforms: From One Extreme To Another (NASDAQ:META)
News

Meta Platforms: From One Extreme To Another (NASDAQ:META)

News
Last updated: 2023/08/03 at 1:45 PM
By News
Share
6 Min Read
SHARE

Contents
Investors Are Overreacting Again, This Time To The UpsideSlowing Growth And High Valuations Imply Negative ReturnsRisks Appear Evenly Balanced

I argued last year that despite the weak long-term growth outlook for Meta Platforms (NASDAQ:META) the stock was likely to post strong returns as valuations rise from discounted levels (see ‘Meta Platforms: Growth No Longer Needed For Solid Long-Term Returns‘). After falling over 50% over the following 8 months to trade at true bargain levels with a free cash flow yield of over 10%, the stock has since rallied 250% to once again trade at a premium to the broader market. The rise in the stock from the lows in October last year represents one of the most staggering reversals of fortune for a mega cap stock I have ever seen, with the company’s value rising almost $600bn over this period. While I believe there are more egregiously overvalued stocks out there, such as Nvidia (NVDA), Tesla (TSLA), and Microsoft (MSFT), Meta is certainly no longer a buy.

Investors Are Overreacting Again, This Time To The Upside

The lows in Meta’s stock in October occurred shortly following the poor earnings report for Q3 2022 which saw revenues decline year over year and profits tank. This led to widespread calls that the company had reached peak sales and would suffer long-term declines sufficient to justify the stock’s extreme discount to the market.

Chart

Meta Price, P/E, P/FCF (Bloomberg)

Fast forward 8 months and investors appear to be overreacting in the opposite direction, bidding up the stock in response to last month’s earnings beat, which saw revenues rise and operating costs fall amid the company’s efficiency drive, leading to a surge in profits. Wall Street analysts have raised their price targets on the stock to a further 14% upside, while the share of bulls has risen 21pp from the October lows and now sits at 86%.

Chart

Meta Analyst Recommendations (Bloomberg)

For large companies like Meta, with annual sales of over $30bn and over 3 billion users, quarterly reports are of little relevance to the stock’s returns over any significant period of time, and extrapolating the recent recovery makes as little sense as extrapolating last year’s earnings slump.

Slowing Growth And High Valuations Imply Negative Returns

While sales and earnings for Q2 were up 11% and 46% y/y respectively, the broader trend remains weak. On a trailing 12-month basis sales were up less than 1% while earnings were down 3%. If one-off losses from writedowns, legal settlements and restructuring are included, earnings are down 33% y/y in TTM terms. Despite the aggressive 4% reduction in share count over this period, unadjusted earnings per share remain down 39% from their 2021 peak.

The company has made efficiency gains from the use of AI which allowed a 14% y/y decline in headcount, and we are likely to see trailing 12-month profit margins rise over the coming quarters. However, such efficiency gains will be hard to repeat going forward, and competition is likely to limit the extent to which the company can increase revenue per user. Meanwhile, the ongoing decline in young Facebook users in developed countries presents an intractable problem for the long term.

Furthermore, continued aggressive buybacks will be difficult to sustain as the company’s balance sheet continues to deteriorate albeit from a strong base. My assumption is that Meta’s sales and earnings growth will continue to slow in line with the broader economy, which looks set to achieve no more than 1% annual growth in real terms.

This is a problem for a company that trades at 36x unadjusted earnings and 34x free cash flow. Even if we generously assume that the one-off losses over the past year will not be repeated, the stock still trades at 26x earnings which is back to a significant premium to the SPX. Even if the company continues to pay out all its free cash flow through buybacks, this would still only amount to 4% annual total real terms, which is just 2 percentage points above 10-year inflation-linked Treasuries. For a stock that can fall by over 70% in less than a year as we saw from late-2021 to late-2022, a 2% risk premium seems wholly inadequate. If investors were to implicitly require 6% annual returns on the stock as has been the long-term overage return for US stocks, the free cash flow yield would have to rise to 5%, requiring a 40% price decline.

Chart

Ajusted PE Ratios (Bloomberg)

Risks Appear Evenly Balanced

There is of course a bullish case for Meta, as for any stock. The company is the world leader in social media engagement which is an addictive yet legal product with almost zero marginal production costs, enabling gross margins of around 80%. This provides the company with a solid financial backing to experiment in other potential growth avenues such as Reality Labs. However, there is also a risk that we see governments take steps to regulate social media companies more tightly on the basis of fighting ‘misinformation’ and mental health concerns among young people. The risk-reward outlook therefore seems particularly poor at current valuations, particularly with cash now offering over 5% with no downside.

Read the full article here

News August 3, 2023 August 3, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Fast Four Quiz: Precision Medicine in Cancer

How much do you know about precision medicine in cancer? Test your knowledge with this quick quiz.
Get Started
Excelerate Energy: Nearby Best Energy-Source Cap-Gain Prospect (NYSE:EE)

The primary focus of this article is Excelerate Energy, Inc. (NYSE:EE). Investment…

Penske Is Steady, But The Road Ahead May Be Bumpy (NYSE:PAG)

Investing Thesis On Wednesday, Penske Automotive Group (NYSE:PAG) released a superficially encouraging…

Top Financial – No, Stop It, This Is Silly (NASDAQ:TOP)

TOP Financial Moves, yes, but why? TOP Financial (NASDAQ:TOP) was quite the…

You Might Also Like

News

2025 Estimated S&P 500 EPS Growth Rate Improved From +9% In July ’25 To +14% On Dec 12 ’25

By News
News

Broadcom: What So Many Analysts & Investors Got Wrong – Buy The Dip (NASDAQ:AVGO)

By News
News

Quantum eMotion Stock (QNCCF): Lofty Valuation For Unproven Business

By News
News

EMD: Not The Best Time For This Emerging Market Income CEF (NYSE:EMD)

By News
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Contact US
More Info
  • Newsletter
  • Finance
  • Investing
  • Small Business
  • Dept Management

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions

Join Community

2025 © wealthbeatnews.com. All Rights Reserved.

Join Us!

Subscribe to our newsletter and never miss our latest news, podcasts etc.

I have read and agree to the terms & conditions
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Lost your password?